JPS6331741B2 - - Google Patents
Info
- Publication number
- JPS6331741B2 JPS6331741B2 JP55012356A JP1235680A JPS6331741B2 JP S6331741 B2 JPS6331741 B2 JP S6331741B2 JP 55012356 A JP55012356 A JP 55012356A JP 1235680 A JP1235680 A JP 1235680A JP S6331741 B2 JPS6331741 B2 JP S6331741B2
- Authority
- JP
- Japan
- Prior art keywords
- isoenzyme
- liquid sample
- antibody
- creatine kinase
- fixed antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010044467 Isoenzymes Proteins 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 26
- 238000004458 analytical method Methods 0.000 claims description 17
- 102000004420 Creatine Kinase Human genes 0.000 claims description 16
- 108010042126 Creatine kinase Proteins 0.000 claims description 16
- 239000011521 glass Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- -1 poly(ethylene terephthalate) Polymers 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 229950006238 nadide Drugs 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 101000572820 Homo sapiens MICOS complex subunit MIC60 Proteins 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 206010028629 Myoglobinuria Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052878 cordierite Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- JSKIRARMQDRGJZ-UHFFFAOYSA-N dimagnesium dioxido-bis[(1-oxido-3-oxo-2,4,6,8,9-pentaoxa-1,3-disila-5,7-dialuminabicyclo[3.3.1]nonan-7-yl)oxy]silane Chemical compound [Mg++].[Mg++].[O-][Si]([O-])(O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2)O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2 JSKIRARMQDRGJZ-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 102000046079 human IMMT Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229940075931 sodium dithionate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229910052596 spinel Inorganic materials 0.000 description 1
- 239000011029 spinel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000010456 wollastonite Substances 0.000 description 1
- 229910052882 wollastonite Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯è©Šæäžã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé
µçŽ
ã®åææ¹æ³ã«é¢ãããããã«è©³ããã¯æ¬çºæã¯åº
å®æäœâã€ãœé µçŽ é¯åäœã«ãã€ãŠè©Šæäžã®ã¯ã¬ã¢
ãã³ãããŒãŒã€ãœé µçŽ ãå®æ§çã«ãããã¯å®éç
ã«åæããããã®æ¹æ³ã«é¢ããã人äœçµç¹ã¯ïŒçš®
é¡ã®ã¯ã¬ã¢ãã³ãããŒãŒïŒCKãE.C.2.7.3.2ãã
ãã¯ã¯ã¬ã¢ãã³ATPâãã©ã³ã¹ããªã¹ããªãªã©
ãŒãŒïŒã®ã€ãœé µçŽ ãå«ãã§ããããšã1964幎ã«ç«
蚌ãããããã®ïŒçš®é¡ã®ã€ãœé µçŽ ã¯ãïŒçš®é¡ã®ç¬
ç¹ãªãµããŠãããïŒããã³ïŒ¢ãïŒéãã«çµåãã
ãã®ã§ããïŒMMïŒMBããã³BBïŒãäžè¿°ã«é¢ã
ãŠã¯ãäŸãã°ãBiochemã»ïŒºïŒ339ïŒ305ïŒ1964ïŒ
ã«èšèŒãããŠããA.ããŒã¬ãŒæ°çã®è«æãClinã»
Chimã»ActaïŒ10ïŒ276ïŒ1964ïŒã«èšèŒãããŠãã
D.H.ããŠãŒã«ããã³J.F.L.ãŽã¢ã³ ãã¬ã¡ã³æ°ã®
è«æããã³NatureïŒ202ïŒ701ïŒ1964ïŒã«èšèŒãã
ãŠããK.ã¹ãžãšãŒãã«ããã³A.ãŽãªã€ãæ°ã®è«
æãåç §ãããããäžèšïŒçš®é¡ã®ã€ãœé µçŽ ã¯è³äž
ã«ååšããéœæ¥µã€ãœé µçŽ ïŒBBïŒãéªšæ Œçäžã«å
åšããγâã°ãããªã³ã«çžåœããé»æ°æ³³åæå床
ãæããã€ãœé µçŽ ïŒMMïŒãããã³ããéªšæ Œçäž
ã«ãŸãå¿çå±€äžã«ååšããäžéã®é»æ°æ³³åæå床
ãæããã€ãœé µçŽ ïŒMBïŒã§ããã 1964幎以åŸ10幎ã®éã«ãCKã€ãœé µçŽ ã®åé¢ã
ãã³å®éãäž»ãšããŠé»æ°æ³³åæ³ã«ãã€ãŠç 究ã
ããMBã€ãœé µçŽ ã¯æ¥æ§å¿çæ¢å¡ã®åŸŽåãææã«
ãŸãæ確ã«ç€ºããšããããšãå ±åããããäžè¿°ã«
é¢ããŠã¯ãäŸãã°ClinïŒChimïŒActaïŒ39ïŒ351
ïŒ1972ïŒã«èšèŒãããŠããA.F.ã¹ãã¹æ°ã®è«æã
ClinïŒChimïŒActaïŒ36ïŒ531ïŒ1972ïŒã«èšèŒãã
ãŠããH.ãœããŒããã³A.ã³ã³ãã€ãã³æ°ã®è«æ
ããã³CirculationïŒ47ïŒ263ïŒ1973ïŒã«èšèŒãã
ãŠããG.S.ã¯ã°ããŒæ°çã®è«æãåç §ããããã
ãŸããCKã€ãœé µçŽ ã®åé¢ã¯ã€ãªã³äº€æã«ã©ã ã¯
ãããã°ã©ãã€ãŒã«ãã€ãŠãéæãããããã®ã€
ãªã³äº€æã«ã©ã ã¯ãããã°ã©ãã€ãŒã«ããCKã€
ãœé µçŽ ã®åé¢ã«ã€ããŠã¯ClinïŒChemïŒïŒ20ïŒ36
ïŒ1974ïŒã«èšèŒãããŠããD.W.ããŒãµãŒæ°ã®è«æ
ãåç §ããããã æè¿ãããŸãäžè¬åãããŠããªãå¥ã®æ¹æ³ã
CKã€ãœé µçŽ ã®åé¢ãããã¯å®éã«é©çšãããã
ãã«ãªã€ãããã®ãããªæ¹æ³ã®ïŒã€ãšããŠå ç«æ»Ž
å®æ³ããªãã¡å ç«é»å®³æ³ãæãããããClinïŒ
ChimïŒActaïŒ58ïŒ223ïŒ1975ïŒã«èšèŒãããŠãã
E.ãžãšãã«ãŒãºâã¬ããŠããã³G.ãã©ã€ãã©ãŒæ°
ã®è«æã«ããã°ã人éã®éªšæ Œçããã³äººéã®è³ã
ãæ¡åãããCKã€ãœé µçŽ çµæ¶ïŒããããMMã
ãã³BBã€ãœé µçŽ ïŒã«å¯Ÿããæè¡æž ããŠãµã®äžã§
çæããããMMããã³BBã€ãœé µçŽ ã¯ãããã
亀ååå¿ãªãããããã«å¯Ÿå¿ããæè¡æž ã«ãã€ãŠ
å®éçã«æ²æ®¿ããã人éã®å¿çããæ¡åããã
MBæ··æã€ãœé µçŽ ã¯ïŒçš®é¡ã®æè¡æž ã®ãããã«ã
ã€ãŠãå šãæ²æ®¿ããªãã€ããããã§åæè¡æž ãšã®
åå¿ã®åŸã®äžæŸã¿æ¶²äžã®éæ²æ®¿æ§ã®æŽ»æ§åºŠã®ããŒ
ã»ã³ããŒãžãã人工混åç©è©Šæäžã®ïŒçš®é¡ã®CK
ã€ãœé µçŽ ã®æ¿åºŠãæ±ããããã倧éå°ã®æè¡æž ã
ååšããå Žåã§ãã€ãŠãåžžã«çŽ10ïŒ ã®æŽ»æ§åºŠãäž
æŸã¿æ¶²äžã«æ®ã€ãŠããã®ã§ããã®æ®ç掻æ§åºŠã¯
MBã®ååšã«ãããã®ã§ãããšä»®å®ããããåŸã€
ãŠãMB掻æ§åºŠã®å€ãæ±ããèšç®ã¯ãã®ãããªä»®
å®ã«åºããŠããã äžè¿°ã®æ¹æ³ã«ãã䌌ãå ç«åŠçæ¹æ³ã«ãKlinïŒ
WochenschrïŒïŒ53ïŒ329ïŒ1975ïŒã«èšèŒãããŠã
ãD.ããŠãŒãã€ã€ãŒæ°çã®è«æã«é瀺ãããŠã
ãæ¹æ³ïŒãã®æ¹æ³ã¯U.ãŠã«ãããŒã°æ°çã®ç±³åœ
ç¹èš±ç¬¬4067775å·ã«ãé瀺ãããŠããïŒãããã
äžèšè«æããã³ç¹èš±ã«ã¯ãMMããã³MBã¯MM
æè¡æž ã«ãã€ãŠå®éçã«æ²æ®¿ããããšãè¿°ã¹ãã
ãŠãããåæ§ã«ãBBããã³MBã¯BBæè¡æž ã«ã
ã€ãŠå®éçã«æ²æ®¿ããããšãè¿°ã¹ãããŠãããã
ãã«ãäžèšè«æããã³ç¹èš±ã®è¡æž è©Šæäžã«ã¯BB
ã¯ååšããªãããšãè¿°ã¹ãããŠãããåŸã€ãŠãäž
èšè«æããã³ç¹èš±ã®æ¹æ³ã«ãããŠã¯ããŸãCK掻
æ§åºŠã®ç·èšãåæãããã次ãã§BBæè¡æž ã«ã
ãæ²æ®¿ã®åŸã®äžæŸã¿æ¶²äžã«æ®çããŠãã掻æ§åºŠã
åæãããããã®ããã«ããŠæ±ããïŒã€ã®å€ã®å·®
ãè¡æž è©Šæäžã®MB掻æ§åºŠãè¡šãããã®ã§ãããš
ããŠããã CKã€ãœé µçŽ ã®æŸå°ç·å ç«åæããŸãç¥ãããŠ
ãããClinïŒChimïŒActaïŒ79ïŒ107ïŒ1977ïŒã«èš
èŒãããŠããD.ããŠãŒãã€ã€ãŒæ°çã®è«æã«ã
ãã°ãMBããã³BBäžã®ãµããŠãããã125
ã§æšèä»ãããBBæè¡æž ãçšããè€æäœ
ïŒdoubleâantibodyïŒæŸå°ç·å ç«åæã«ãã€ãŠå®
éãããããŸãã 125ã§æšèä»ãããCKã€ãœ
é µçŽ ã䜿çšããMBã®æ®æç眮ææŸå°ç·å ç«åæ
ãR.ãããŒãæ°çã«ãã€ãŠClinïŒChimïŒActaïŒ
83ïŒ141ïŒ1978ïŒã«å ±åããããããã«ã 125ã§
æšèä»ãããã€ãœé µçŽ ã䜿çšããMMããã³BB
ã«ã€ããŠè€æäœæŸå°ç·å ç«åæãA.C.ãŽã¢ã³
ã¹ã¿ã€ã«ãã²ã æ°çã«ãã€ãŠClinïŒChemïŒïŒ24ïŒ
414ïŒ1978ïŒã«ããŸãM.H.ããŽã¢ã€ã°æ°çã«ãã€
ãŠClinïŒChemïŒïŒ24ïŒ422ïŒ1978ïŒã«å ±åãããã ããã«ãCKã€ãœé µçŽ ã®å®éã®ããã®å ç«åžç
å€æ³ãJ.ããªã¢ãŒãæ°çã«ãã€ãŠArchïŒ
BiochemïŒBiophysïŒïŒ191ïŒ90ïŒ1978ïŒã«å ±åã
ããããã®æ¹æ³ã«ãããŠã¯ããŸãçŽç²ãªMMãã
ã³BBæè¡æž ã調補ãããåæè¡æž ã¯ããã¢ã·ã¢
ã³ã§æŽ»æ§åããã»ãã¢ããŒãº4BïŒSepharose4BïŒ
ã«å¥ã ã«çµåããïŒçš®é¡ã®å ç«åžçå€ã調補ãã
ãã次ã«è©Šæäžã®CKã€ãœé µçŽ ã®æŽ»æ§åºŠã®ç·èšã
åæãããããã®åŸãè©Šæã®ã¢ãªã³ãŒããåå ç«
åžçå€ã«ã©ã ã«éãããããªãŒã®ã€ãœé µçŽ ãåã«
ã©ã ããæŽãèœãããåã«ã©ã ã«ã€ããŠããªãŒã®
ã€ãœé µçŽ ã®æŽ»æ§åºŠãåæããããMMæè¡æž ãå«
ãã«ã©ã ããæ±ããããããªãŒã®ã€ãœé µçŽ ã®æŽ»æ§
床ã¯BB掻æ§åºŠãè¡šãããBBæè¡æž ãå«ãã«ã©
ã ããæ±ããããããªãŒã®ã€ãœé µçŽ ã®æŽ»æ§åºŠã¯
MM掻æ§åºŠãè¡šãããåŸã€ãŠãMB掻æ§åºŠã¯å ã«
æ±ããè©Šæäžã®CKã€ãœé µçŽ ã®æŽ»æ§åºŠã®ç·èšãã
MM掻æ§åºŠããã³BB掻æ§åºŠãåŒãããšã«ãã€ãŠ
æ±ããããã 以äžè¿°ã¹ãåŸæ¥ã®æ¹æ³ã®ãããã«ãããŠããã€
ãœé µçŽ âæäœé¯åäœã®ã€ãœé µçŽ 掻æ§åºŠã¯ååšããª
ããšä»®å®ãããããããããã¯ååšããªãããšã
ç¥ãããŠãããå¿è«ãããã¯æ¢ç¥ã®æäœã«ãã
CKã€ãœé µçŽ ã®äžæŽ»æ§åã«ççŸãããã®ã§ã¯ãªãã
äžè¿°ã«ã€ããŠã¯ãäŸãã°ãã¢ã«ããã㯠ãã¬ã¹
瀟ïŒAcademic PressïŒNew YorkïŒ1977幎åºç
ã®C.A.ãŠã€ãªã¢ã ãºããã³M.W.ããšã€ã¹æ°å ±è
ãå ç«åŠããã³å ç«ååŠã«ãããæ¹æ³ãã第ïŒå·»ã
第317é ïŒããŒã¬ã¢ã³ ãã¬ã¹ç€Ÿãã·ã³ããžãŠã
åºçéšïŒPergamon PressïŒSymposium
Publications DivisionïŒOxfordïŒ1967幎åºçã®
ã»ã·ãããŒæ°èãçç©åŠç掻æ§ååã«å¯Ÿããæ
äœãïŒ1965幎ïŒæ21ã24æ¥ã«ãŠã€ãŒã³ã§éå¬ãã
ããšãŒããçç©ååŠäŒé£çã®ç¬¬ïŒåéäŒã®äŒå ±ã§
ããïŒã第ïŒå·»ã第87é ïŒAnnïŒïŒ®ïŒïŒ¹ïŒAcadïŒ
SciïŒïŒ103(2)ïŒ500ïŒ1963ïŒã«èšèŒãããŠããB.ã·
ãããŒæ°ã®è«æïŒããã³ãžãšã³ãŠã€ãªãŒã»ã¢ã³
ãã»ãµã³ãºç€ŸïŒJohn WileyïŒSonsïŒNew
YorkïŒ1977幎åºçã®M.R.J.ãµã«ãã³æ°èãé µçŽ
ããã³ãã®æäœã®å ç«ååŠãã第104é ãåç §ãã
ããã ãã®ããã«ãæäœâã€ãœé µçŽ é¯åäœã®CKã€ãœ
é µçŽ æŽ»æ§åºŠãåæããããšã«ãã€ãŠCKã€ãœé µçŽ
ã®ååšãç«èšŒããããšããå ±åã¯åŸæ¥ç¥ãããŠã
ãªãã åŸã€ãŠãæ¬çºæã®ç®çã¯CKã€ãœé µçŽ ã®åææ¹
æ³ãæäŸããããšã«ããã æ¬çºæã®å¥ã®ç®çã¯åºå®æäœâã€ãœé µçŽ é¯åäœ
ã«ãã€ãŠCKã€ãœé µçŽ ãåæããããã®æ¹æ³ãæ
äŸããããšã«ããã æ¬çºæã®ããã«å¥ã®ç®çã¯åæå¯èœãªã€ãœé µçŽ
掻æ§åºŠãä¿æããŠããåºå®æäœâã€ãœé µçŽ é¯åäœ
ã«ãã€ãŠCKã€ãœé µçŽ ãåæããããã®æ¹æ³ãæ
äŸããããšã«ããã ãããç®çããã³ãã®ä»ã®ç®çã¯æ¬æ现æžãã
æããã«ãªãã§ãããã å šãæå€ã«ããç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãªåº
å®æäœã¯ãã®ã€ãœé µçŽ ãšçµåããŠãåæå¯èœãªã€
ãœé µçŽ 掻æ§åºŠãä¿æããŠããåºå®æäœâã€ãœé µçŽ
é¯åäœãçæããããšãããªãã¡ãã€ãœé µçŽ 掻æ§
床ãå®å šã«é»å®³ããããšãªãåºå®æäœâã€ãœé µçŽ
é¯åäœãçæããããšãèŠåºãããã åŸã€ãŠãæ¬çºæã¯ç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãª
åºå®æäœã液äœè©Šæã«æ¥è§Šããã次ãã§äžèšåºå®
æäœãããã¯çããåºå®æäœâã€ãœé µçŽ é¯åäœã
ããã¯äžèšåºå®æäœãšäžèšåºå®æäœâã€ãœé µçŽ é¯
åäœã®æ··åç©ãåé¢ãããããåŸåé¢ããç©è³ªã®
ã€ãœé µçŽ 掻æ§åºŠãåæããããšãããªã液äœè©Šæ
äžã®CKã€ãœé µçŽ ã®åææ¹æ³ãæäŸãããã®ã§ã
ãã ãŸããæ¬çºæ㯠 液äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³ãŒã
ããç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãªåºå®æäœãšæ··
åãã  äžèšã¹ãããã§åŸãããæ··åç©ãå¹é€ãã  äžèšã¹ãããã§åŸãããå¹é€æ··åç©ããäž
èšåºå®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ
é¯åäœãããã¯äžèšåºå®æäœãšäžèšåºå®æäœâ
ã€ãœé µçŽ é¯åäœã®æ··åç©ãåé¢ãããããåŸ ïŒ€ äžèšã¹ãããã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻
æ§åºŠãåæãã ããšãããªã液äœè©Šæäžã®CKã€ãœé µçŽ ã®åææ¹
æ³ãæäŸãããã®ã§ããã 人éã®è¡æž äžã®åçš®CKã€ãœé µçŽ ãå®æ§çã«ã
ããã¯å®éçã«åæããããšã¯ãå¿çæ¢å¡ãå¿è
é害ãé²è¡æ§çç°æ é€çãç®èççãããªã°ãã
ã³å°¿çã䌎ãçŸç ãæªæ§é«ç±çã®çš®ã ã®ç æ°ã蚺
æããã®ã«æå¹ã§ããã æ¬æ现æžã§äœ¿çšããã液äœè©Šæããšããçšèª
ã¯ãæ¬æ¥æ¶²äœã§ããè©Šæãšè©Šææ¡åã®åŸæ¶²äœã®ç¶
æ ã«å€æãããè©Šæã®ãããããæå³ãããåŸã€
ãŠã液äœè©Šæã¯äººäœçµç¹ã®æœåºç©ã§ãã€ãŠããã
ãã人éã®è¡æž ãèžè液ãå°¿ãèæ€æ¶²ãããã¯ç²Ÿ
液ã§ãã€ãŠããããå®éã«ã¯ã液äœè©Šæã¯ã»ãšã
ã©ã®å Žåè¡æž ã§ããã 液äœè©Šæäžã®CKã€ãœé µçŽ 掻æ§åºŠã®ç·èšãåæ
ããã®ãæãŸãããããããã¯å¿ èŠã§ããå Žåã
ããã以äžã«è¿°ã¹ãããã«ãæ¬çºæã¯ãã®ãããª
åæã®ããã®æ¹æ³ãæäŸãããã®ã§ãããããã
ãªããã液äœè©Šæäžã®CKã€ãœé µçŽ 掻æ§åºŠã®ç·èš
ã®åæã¯æ¢ç¥ã®æ¹æ³ã«ãã€ãŠè¡ãªã€ãŠãããã
CKã€ãœé µçŽ 掻æ§åºŠã®ç·èšã®åæã¯å Žåã«å¿ããŠ
æ¬çºæã®æ¹æ³ãè¡ãªãåããããã¯æ¬çºæã®æ¹æ³
ãè¡ã€ãŠããéããããã¯ãæ¬çºæã®æ¹æ³ãè¡ãª
ã€ãåŸè¡ãªãããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã¹ãããã¯æ¶²äœè©Šæããã
ã¯ãã®ã¢ãªã³ãŒããç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãª
åºå®æäœãšæ··åããããšãããªããäžè¬ã«ãç¹å®
ã®CKã€ãœé µçŽ ã«ç¹ç°ãªæäœã¯æ¢ç¥ã®æ¹æ³ã«åŸã€
ãŠèª¿è£œããããããããªãããäžè¬ã«åŸãããæ
è¡æž ãããã«åŠçããŠç²Ÿè£œæäœãšããå¿ èŠã¯ãª
ãã䟿å®äžåºå®æäœã¯æè¡æž ããçŽæ¥èª¿è£œãã
ããåŸã€ãŠãåºå®æäœã¯å¿ ç¶çã«äŸãã°ã°ãããª
ã³ã®ãããªæ¬çºæã®æ¹æ³ã«ã¯é¢äžããªãçš®ã ã®ã¿
ã€ãã®åºå®ã¿ã³ãã¯è³ªãšå ±åããŠãããæè¡æž ã
ãçŽæ¥èª¿è£œãããåºå®æäœã¯ã€ãœé µçŽ 掻æ§åºŠã®å
äœåœãã®å¿ èŠéã粟補æè¡æž ãã調補ãããåºå®
æäœãããå€ããªãããåºå®æäœã¯çŽåºŠãé«ãã
ã®ã§ããå¿ èŠã¯ãªããåŸã€ãŠãæ¬æ现æžã§äœ¿çšã
ããåºå®æäœããšããçšèªã¯ãç¹å®ã®çŽåºŠã®åºå®
æäœãæå³ãããã®ã§ã¯ãªãã æäœã®åºå®ã¯æ¢ç¥ã®æ¹æ³ã«åŸã€ãŠè¡ãªãããã
æ害ãªäœçšãé¿ãããããªãã°æ äœããã³åºå®æ¹
æ³ã¯ããããéèŠãªãã®ã§ã¯ãªããåŸã€ãŠãæ äœ
ã¯ææ©ç©ãããã¯ç¡æ©ç©ã®ãããã§ãã€ãŠããã
ããå€åæ§ç©è³ªãããã¯éå€åæ§ç©è³ªã®ãããã§
ãã€ãŠããããããŸããããªã圢ç¶ã®ãã®ã§ãã€
ãŠããããæ äœã¯åŸ®ç²ããç²ãç²åãŸã§ã®ç²åç¶
ç©è³ªã§ãã€ãŠãããããå¹³æ ãªãŸãã¯æ¹Ÿæ²ããã·
ãŒãããã¬ããã®ãããªé£ç¶çãªé 圢åãããã
ã¯ç©åœ¢ç¶ãŸãã¯åçç¶ã®ããŠãŒããè€éãªã¢ããª
ã¹ã®ãããªç«äœçç©åã§ãã€ãŠãããã䟿å©ã§ã
ãã®ã§ã»ãšãã©ã®å Žåæ äœãšããŠäŸãã°ç±³åœç¯©èŠ
æ Œã§çŽ20ä¹è³çŽ100ã¡ãã·ãŠã®æ¯èŒç埮现ãªç²å
ç¶ç©è³ªãçšããããã é©åœãªææ©æ äœã®äŸãšããŠãç¹ã«ããªïŒãšãã¬
ã³ãã¬ãã¿ã¬ãŒãïŒã®ãããªããªãšã¹ãã«ïŒãã€
ãã³ïŒããã³ãã€ãã³6.6ã®ãããªããªã¢ããïŒ
ããªã¢ã¯ãªã¬ãŒãïŒããªã¡ã¿ã¯ãªã¬ãŒãïŒã¢ã¬ã
ãŒã¹ã²ã«ïŒããã¹ãã©ã³ã²ã«ïŒããªãšãã¬ã³ãã
ãªãããã¬ã³ãããªããã³ããã³ããªãã¿ãžãšã³
ã®ãããªããªãªã¬ãã€ã³ïŒããªã¹ãã¬ã³ïŒããª
ïŒããã«ã¯ãã©ã€ãïŒïŒããªïŒãããªãã³ã¯ãã©ã€
ãïŒçãæããããã ç¡æ©æ äœã¯ãçªè³ªç©è³ªãšéçªè³ªéå±é žåç©ã«å
ãããããçªè³ªæ äœã®äŸãšããŠãã¬ã©ã¹ãã·ãª
ã«ãçªç°ç³ããã³ããã€ããè«éç³çãæããã
ããéçªè³ªéå±é žåç©æ äœã®äŸãšããŠãç¹ã«ã¢ã«
ãããå°æ¶ç³ãçç°ç³ãé žåããã±ã«ããã¿ã
ã¢ããžã«ã³ãã¢çãæãããããç¡æ©æ äœã®æ¹ã
ãã奜ãŸãããç¡æ©æ äœã®äžã§ãçªè³ªç©è³ªãç¹ã«
奜ãŸãããæã奜ãŸããæ äœã¯ã·ãªã«ãšã¬ã©ã¹ã§
ãããæ äœã®åäœå®¹ç©ãããã¯åäœééåœãã®æ
äœã®éãå€ããªãããã«ãæ äœã¯å€å質ã§ããã®
ã奜ãŸããã äžè¬ã«ãæäœã®åºå®ã¯ç°¡åãªåžçããååŠççµ
åãŸã§ã®æ¢ç¥ã®æ¹æ³ã®ãããã«ãã€ãŠè¡ãªã€ãŠã
ãããåšç¥ã®ããã«ãåžçã¯äžè¬ã«åºå®ãããæ
äœã®æ°Žæº¶æ¶²ïŒæè¡æž ïŒãæã¿ã®ïŒãããã¯æ倧
ã®ïŒåºå®åºŠãéæãããã®ã«å åãªæéæ äœã«æ¥
觊ãããããšãããªããååŠççµåã¯ãäžè¬ã«æ
äœãïŒçš®ãããã¯ïŒçš®ä»¥äžã®ååç©ã§åŠçããã
ã®åŸåŠçããæ äœãæäœã®æ°Žæº¶æ¶²ã«æ¥è§Šãããã
ãšãããªããæ äœãç¹ã«ç¡æ©æ äœãåŠçããã®ã«
çšããããååç©ã®äŸãšããŠãâãžã¢ãã·ãžã³
ïŒç±³åœç¹èš±ç¬¬3983000å·åç §ïŒãã€ãœã·ã¢ããŒãã
ãªããŒïŒç±³åœç¹èš±ç¬¬4071409å·åç §ïŒãã·ã©ã³ïŒç±³
åœç¹èš±ç¬¬3519538å·åç §ïŒçãæãããããæ äœ
ãåŠçããã®ã«äœ¿çšããååç©ã«ã€ããŠã¯ãç±³åœ
ç¹èš±ç¬¬3930951ããã³3933589å·ããŸãåç §ããã
ãã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã®ã¹ãããã¯ç¬¬ïŒã®ã¹ãã
ãã§åŸãããæ··åç©ãå¹é€ããããšãããªããäž
è¬ã«å¹é€ã¯çŽïŒâä¹è³çŽ40âã®æž©åºŠã§è¡ãªãã
ããç¹ã«å¥œãŸããå¹é€æž©åºŠã¯37âã§ãããå¹é€æ
éã¯éé¢ãªãã®ã§ã¯ãªããäžè¬ã«çŽ0.5æéä¹è³
çŽïŒæéã§ãããããããªãããã»ãšãã©ã®å Žå
å¹é€æéã¯äŸ¿å®äžïŒæé以å ãšãããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã®ã¹ãããã«ãããŠã¯ãåº
å®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ é¯åäœ
ãããã¯ãããã®æ··åç©ã第ïŒã¹ãããå¹é€æ··å
ç©ããåé¢ãããããã®åé¢ã¯é å¿åé¢ãæ¿Ÿéã®
ãããªæ¢ç¥ã®åé¢æ¹æ³ã®ãããã«ãã€ãŠè¡ãªã€ãŠ
ãããããé å¿åé¢ãç¹ã«æå¹ã§ãããåŸã€ãŠé
å¿åé¢ãç¹ã«å¥œãŸããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã®ã¹ãããã¯ç¬¬ïŒã®ã¹ãã
ãã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻æ§åºŠãåæããã
ãšãããªãããã®åæã¯æ¢ç¥ã®æ¹æ³ã®ãããã«ã
ã€ãŠè¡ãªã€ãŠããããããŸãå®æ§çã«è¡ãªã€ãŠã
ãããããããã¯å®éçã«è¡ãªã€ãŠãããã CKã€ãœé µçŽ ã¯äžèšã®åå¿ã®è§ŠåªãšããŠäœçšã
ãããšã¯åšç¥ã§ããã ïŒäœããäžèšADPããã³ATPã¯ããããã¢ã
ãã·ã³5â²âäºçé žããã³ã¢ããã·ã³5â²âäžçé žã
è¡šãããïŒ ããã«ãäžèšã®åå¿ããŸãåšç¥ã§ããã äœãäžèšHKã¯ãããœãããŒãŒãè¡šããã
NAD+ããã³NADHã¯ããããé žåããã³éå
ç¶æ ã®ãã³ãã³ã¢ããã¢ããã³ãžãã¯ã¬ãªããã
è¡šããããŸãâïŒâPDHã¯ã°ã«ã³ãŒã¹âïŒâ
çé žããããã²ããŒãŒãè¡šãããïŒ åŸã€ãŠãCKã€ãœé µçŽ ãåæããã®ã«ç¹ã«æå¹
ã§ããåžè²©ã®åºè³ªã¯ã¯ã¬ã¢ãã³çé žãADPãã°
ã«ã³ãŒã¹ãNAD+ããããœãããŒãŒããã³ã°ã«ã³
ãŒã¹âïŒâçé žããããã²ããŒãŒãå«ãã§ããã
ãã®ãããªåºè³ªã䜿çšããããšã«ãã€ãŠNADH
ã340nmã§ã®åå 枬å æ³ãããã¯è¢å åææ³ã«ã
ã€ãŠå®¹æã«æ€åºããªãã¡åæããããšãã§ããã
äžèšåºè³ªã®åžè²©åã®äžäŸã¯ã¯ãŒã·ã³ãã³ãã€ã¢ã°
ãã¹ãã€ãã¯ã¹ç€ŸïŒWorthington DiagnosticsïŒ
FreeholdïŒNew Jersey 07728ïŒã®ã¹ã¿ããã¶ã€
ã ïŒSTATZYMEãç»é²åæšïŒCRKnâïŒã§ã
ããäžèšNAD+ããã³ïŒ§âïŒâPDHã¯ãããã
NADP+ããã³NADP+ã«ç¹ç°ãªé µçŽ ã«çœ®ãæã
ãããŠããŠãããã å¿è«ãä»ã®åºè³ªãçšããããšãå¯èœã§ããã
NADH以å€ã®ç©è³ªãæ€åºããããšãå¯èœã§ããã
ããã«ãNADHã®ååšã¯ä»ã®æ¹æ³ã«ãã€ãŠãæ€
åºããããšãã§ãããäŸãã°ãNADHã«ãã€ãŠ
éå ããããææãåºè³ªæº¶æ¶²ã«å«ãŸããããšã«ã
ããåå å 床èšã䜿çšããæ¯è²æ³ã«ãã€ãŠ
NADHãåæããããšãã§ãããäžèšææã®äŸ
ãšããŠãâã¢ã€ãªããããããã©ãŸãªãŠã ãã€
ãªã¬ãããããããã«âããã©ãŸãªãŠã ã¯ãã©ã€
ããããã¯ããšããžã³ã¡ããµã«ããšãŒããšçµåã
ãä»ã®é©åœãªããã©ãŸãªãŠã å¡©ã®ãããªNADH
çµåæ§æ¯è²ææ調åç©ãæããããããŸããäžèš
âïŒâPDHã觊åªãšããåå¿ããã³äžèšHK
ã觊åªãšããåå¿ã¯ãã¯ã¬ã¢ãã³ã®ãããªäžèš
CKã觊åªãšããåå¿ã®çæç©ãšçµåããè©Šè¬ã
çšããããšã«ãã€ãŠåé¿ããããšãã§ãããäžèš
è©Šè¬ãšããŠãαâããããŒã«ãšãžã¢ã»ãã«ã䜵çš
ãããããã®ïŒã€ã®ååç©ã¯ã¯ã¬ã¢ãã³ãšçµåã
ãŠãã³ã¯è²ã®é¯åäœãçæããã çšããããåææ¹æ³ã«ããããããåŸãããã
ãŒã¿ã¯åšç¥ã®æ¹æ³ã«åŸã€ãŠæ€éç·ãšæ¯èŒãããã
ãã«ãã€ãŠCKã€ãœé µçŽ ãå®éãããã æ¬çºæã®æ¹æ³ã«ãã€ãŠCKã€ãœé µçŽ 掻æ§åºŠã®ç·
èšãåæããã®ã«ã¯ãMMããã³BBã€ãœé µçŽ ã
ãããã«ç¹ç°ãªåºå®æäœã䜿çšããŠãåäžæ¶²äœè©Š
æã«ã€ããŠæ¬çºæã®æ¹æ³ãè¡ãªãããšãå¿ èŠãªã
ãã§ãããå¿è«ãäžããããè©Šæã«ã€ããŠãŸã
MMããã³BBã®ããããäžæ¹ã«ç¹ç°ãªåºå®æäœ
ã䜿çšããŠæ¬çºæã®æ¹æ³ãè¡ãªããã次ã«åäžè©Š
æã«ã€ããŠMMããã³BBã®ããäžæ¹ã®ç¹ç°ãªåº
å®æäœã䜿çšããŠæ¬çºæã®æ¹æ³ãè¡ãªããããã
ãããªãããMMããã³BBããããã«ç¹ç°ãªåº
å®æäœãæ··åããåŸãããæ··åç©ã䜿çšããŠæ¬çº
æã®æ¹æ³ãè¡ãªãã®ããã䟿å©ã§ããã 次ã«å®æœäŸã«ãã€ãŠæ¬çºæã説æããã å®æœäŸ çã®çèããMMåã®CKã€ãœé µçŽ ãåé¢ãã
ArchïŒBiochemïŒBiophysïŒïŒ150ïŒ648ïŒ1972ïŒ
ã«èšèŒãããŠããH.J.ããŠãŒãã«æ°çã®è«æã®æ¹
æ³ã«åŸã€ãŠç²Ÿè£œããã次ã«ãã®ã€ãœé µçŽ ã«å¯Ÿãã
æäœãæšæºæ³ã«åŸã€ãŠãŠãµã®äžã§çæãããåºå®
æè¡æž ïŒåºå®æäœãIMAïŒã¯ãŠã€ãŒã¿ã«ããã³
ãã€ã«ããŒãæ°ã®æ¹æ³ã«åŸã€ãŠèª¿è£œããïŒã¢ã«ã
ããã¯ãã¬ã¹ç€Ÿ1974幎åºçã®B.ãžã€ã³ããŒãã
ã³M.ãŠã€ã«ããšãã¯æ°å ±èãé µçŽ åŠã«ãããæ¹
æ³ãã第34Bå·»ã第59ã72é åç §ã®ããšïŒããã®å Ž
åãæ äœãšããŠå¹³åçŽåŸã550â«ã®å¶åŸ¡ããã现
åãæããå¹³åç²åãµã€ãºãïŒãã¯ãã³ã®ã¬ã©ã¹
ã䜿çšãããã®ã¬ã©ã¹ãšæè¡æž ã®å²åãã¬ã©ã¹ïŒ
ïœã«å¯ŸããŠæè¡æž ïŒmlãšããããã®åºå®æäœã®èª¿
補ãç°¡åã«èª¬æãããšããŸãäžèšã¬ã©ã¹ãïŒïŒ ç¡
é žæº¶æ¶²äžã§æž æµã«ããæŽæµãPH3.45ã®10ïŒ Î³âã¢
ãããããã«ããªãšããã·ã·ã©ã³æ°Žæº¶æ¶²ã§åŠçã
ããåŸãããã·ã©ã³åã¬ã©ã¹ãæå»å€ãšããŠããª
ãšãã«ã¢ãã³ã10容éïŒ å«ãã¯ãããã«ã äžã§ïŒ°
âããããã³ãŸã€ã«ã¯ãã©ã€ããšåå¿ãããã次
ã«ïŒ°âããããã³ãŸã€ã«ã¢ããã¢ã«ãã«ãçãã
ã¬ã©ã¹ã10ïŒ ãžããªã³é žãããªãŠã 氎溶液ã§åŠç
ããŠãããåºãéå ãããåŸãããâã¢ããã
ã³ãŸã€ã«ã¢ããã¢ã«ãã«ãçããã¬ã©ã¹ãå¡©é žãš
äºç¡é žãããªãŠã ããçããããäºç¡é žã§ãžã¢ãŸ
åããããžã¢ãŸåçæç©ãæŽæµããPHïŒãïŒã®æ
è¡æž äžã«å ¥ãããåŸãããåºå®æäœãé å¿åé¢ã«
ãã€ãŠåé¢ããæŽæµãã0.01Mã®çé žå¡©ãç·©è¡å€
ãšããPH7.4ã®å¡©æ°ŽïŒç·©è¡å¡©æ°ŽïŒäžã«ãã®ç·©è¡å¡©
æ°ŽïŒmlã«ã€ãIMA10mgã®å²åã§æžæ¿ããããã
ã®ããã«ããŠåŸãIMAã¯ã¬ã©ã¹100mgã«ã€ã32mg
ã®ã¿ã³ãã¯è³ªãå«ãã§ããã æ¢ç¥ã®æ¿åºŠã®äžèšç²Ÿè£œMMã€ãœé µçŽ ãå«æãã
溶液0.5mlã«äžèšIMAæžæ¿æ¶²0.5mlãæ·»å ãããåŸ
ãããæ··åç©ã37âã§30åéå¹é€ããããã®åŸæ··
åç©ãé å¿åé¢ããIMAãšIMAâMMé¯åäœã®
æ··åç©ã®å¡ãåŸãããã®å¡ãåã³PH7.4ã®ç·©è¡å¡©
æ°Žäžã«æžæ¿ãããé å¿åé¢ã«ãã€ãŠåæ²æ®¿ãããŠ
IMAãšç¹ç°çã«çµåããªãé µçŽ ãããã¯ãã®ä»
ã®ã¿ã³ãã¯è³ªãé€å»ããããã®åŸå¡ãã¹ã¿ããã¶
ã€ã CPKnâïŒã1.0mläžã«æžæ¿ããã宀枩ïŒ25
âïŒã§å¹é€ããããã®å Žåãå¥ã ã®è©ŠæãïŒïŒ
ïŒïŒ10ããã³20åéå¹é€ãããå¹é€ã®åŸãæ··åç©
ãé å¿åé¢ããåŸãããäžæŸã¿æ¶²ã®340nmã«ãã
ãå åŠæ¿åºŠãåå å 床èšã«ãã€ãŠæž¬å®ãããåæ¢
ç¥ã®æ¿åºŠã«ã€ããŠãäžèšåå¹é€æéã«ã€ããŠã®æž¬
å®çµæãå¹³åããŠïŒåéåœãã®â³O.D.ãæ±ããã
ãããã®å Žåããã©ã³ã¯è©Šéšãè¡ãªãã枬å®å€ã
ããã©ã³ã¯å€ãåŒããŠäžèšã®è¡šã«ç€ºããããã©ã³
ã¯è£æ£å€ãåŸãã ãè¡šã äžè¡šã®ããŒã¿ãçšããŠãåšç¥ã®æ¹æ³ã«åŸã€ãŠæ€
éç·ãäœè£œããã MMã€ãœé µçŽ 溶液ã®ä»£ããã«çã®è³ããåé¢ã
ãBBã€ãœé µçŽ ã®æº¶æ¶²ãçšããããšä»¥å€ã¯äžè¿°ãš
åæ§ã«ããŠäžèšã®ããŒã¿ãåŸãã ãè¡šã ãã®ããã«ã䜿çšããIMAã§ã¯å€å°ã®äº€åå
å¿ãèŠããããã®äº€ååå¿ã¯çŽ15ïŒ ã§ãã€ãã
ã®åææ¹æ³ã«é¢ãããããã«è©³ããã¯æ¬çºæã¯åº
å®æäœâã€ãœé µçŽ é¯åäœã«ãã€ãŠè©Šæäžã®ã¯ã¬ã¢
ãã³ãããŒãŒã€ãœé µçŽ ãå®æ§çã«ãããã¯å®éç
ã«åæããããã®æ¹æ³ã«é¢ããã人äœçµç¹ã¯ïŒçš®
é¡ã®ã¯ã¬ã¢ãã³ãããŒãŒïŒCKãE.C.2.7.3.2ãã
ãã¯ã¯ã¬ã¢ãã³ATPâãã©ã³ã¹ããªã¹ããªãªã©
ãŒãŒïŒã®ã€ãœé µçŽ ãå«ãã§ããããšã1964幎ã«ç«
蚌ãããããã®ïŒçš®é¡ã®ã€ãœé µçŽ ã¯ãïŒçš®é¡ã®ç¬
ç¹ãªãµããŠãããïŒããã³ïŒ¢ãïŒéãã«çµåãã
ãã®ã§ããïŒMMïŒMBããã³BBïŒãäžè¿°ã«é¢ã
ãŠã¯ãäŸãã°ãBiochemã»ïŒºïŒ339ïŒ305ïŒ1964ïŒ
ã«èšèŒãããŠããA.ããŒã¬ãŒæ°çã®è«æãClinã»
Chimã»ActaïŒ10ïŒ276ïŒ1964ïŒã«èšèŒãããŠãã
D.H.ããŠãŒã«ããã³J.F.L.ãŽã¢ã³ ãã¬ã¡ã³æ°ã®
è«æããã³NatureïŒ202ïŒ701ïŒ1964ïŒã«èšèŒãã
ãŠããK.ã¹ãžãšãŒãã«ããã³A.ãŽãªã€ãæ°ã®è«
æãåç §ãããããäžèšïŒçš®é¡ã®ã€ãœé µçŽ ã¯è³äž
ã«ååšããéœæ¥µã€ãœé µçŽ ïŒBBïŒãéªšæ Œçäžã«å
åšããγâã°ãããªã³ã«çžåœããé»æ°æ³³åæå床
ãæããã€ãœé µçŽ ïŒMMïŒãããã³ããéªšæ Œçäž
ã«ãŸãå¿çå±€äžã«ååšããäžéã®é»æ°æ³³åæå床
ãæããã€ãœé µçŽ ïŒMBïŒã§ããã 1964幎以åŸ10幎ã®éã«ãCKã€ãœé µçŽ ã®åé¢ã
ãã³å®éãäž»ãšããŠé»æ°æ³³åæ³ã«ãã€ãŠç 究ã
ããMBã€ãœé µçŽ ã¯æ¥æ§å¿çæ¢å¡ã®åŸŽåãææã«
ãŸãæ確ã«ç€ºããšããããšãå ±åããããäžè¿°ã«
é¢ããŠã¯ãäŸãã°ClinïŒChimïŒActaïŒ39ïŒ351
ïŒ1972ïŒã«èšèŒãããŠããA.F.ã¹ãã¹æ°ã®è«æã
ClinïŒChimïŒActaïŒ36ïŒ531ïŒ1972ïŒã«èšèŒãã
ãŠããH.ãœããŒããã³A.ã³ã³ãã€ãã³æ°ã®è«æ
ããã³CirculationïŒ47ïŒ263ïŒ1973ïŒã«èšèŒãã
ãŠããG.S.ã¯ã°ããŒæ°çã®è«æãåç §ããããã
ãŸããCKã€ãœé µçŽ ã®åé¢ã¯ã€ãªã³äº€æã«ã©ã ã¯
ãããã°ã©ãã€ãŒã«ãã€ãŠãéæãããããã®ã€
ãªã³äº€æã«ã©ã ã¯ãããã°ã©ãã€ãŒã«ããCKã€
ãœé µçŽ ã®åé¢ã«ã€ããŠã¯ClinïŒChemïŒïŒ20ïŒ36
ïŒ1974ïŒã«èšèŒãããŠããD.W.ããŒãµãŒæ°ã®è«æ
ãåç §ããããã æè¿ãããŸãäžè¬åãããŠããªãå¥ã®æ¹æ³ã
CKã€ãœé µçŽ ã®åé¢ãããã¯å®éã«é©çšãããã
ãã«ãªã€ãããã®ãããªæ¹æ³ã®ïŒã€ãšããŠå ç«æ»Ž
å®æ³ããªãã¡å ç«é»å®³æ³ãæãããããClinïŒ
ChimïŒActaïŒ58ïŒ223ïŒ1975ïŒã«èšèŒãããŠãã
E.ãžãšãã«ãŒãºâã¬ããŠããã³G.ãã©ã€ãã©ãŒæ°
ã®è«æã«ããã°ã人éã®éªšæ Œçããã³äººéã®è³ã
ãæ¡åãããCKã€ãœé µçŽ çµæ¶ïŒããããMMã
ãã³BBã€ãœé µçŽ ïŒã«å¯Ÿããæè¡æž ããŠãµã®äžã§
çæããããMMããã³BBã€ãœé µçŽ ã¯ãããã
亀ååå¿ãªãããããã«å¯Ÿå¿ããæè¡æž ã«ãã€ãŠ
å®éçã«æ²æ®¿ããã人éã®å¿çããæ¡åããã
MBæ··æã€ãœé µçŽ ã¯ïŒçš®é¡ã®æè¡æž ã®ãããã«ã
ã€ãŠãå šãæ²æ®¿ããªãã€ããããã§åæè¡æž ãšã®
åå¿ã®åŸã®äžæŸã¿æ¶²äžã®éæ²æ®¿æ§ã®æŽ»æ§åºŠã®ããŒ
ã»ã³ããŒãžãã人工混åç©è©Šæäžã®ïŒçš®é¡ã®CK
ã€ãœé µçŽ ã®æ¿åºŠãæ±ããããã倧éå°ã®æè¡æž ã
ååšããå Žåã§ãã€ãŠãåžžã«çŽ10ïŒ ã®æŽ»æ§åºŠãäž
æŸã¿æ¶²äžã«æ®ã€ãŠããã®ã§ããã®æ®ç掻æ§åºŠã¯
MBã®ååšã«ãããã®ã§ãããšä»®å®ããããåŸã€
ãŠãMB掻æ§åºŠã®å€ãæ±ããèšç®ã¯ãã®ãããªä»®
å®ã«åºããŠããã äžè¿°ã®æ¹æ³ã«ãã䌌ãå ç«åŠçæ¹æ³ã«ãKlinïŒ
WochenschrïŒïŒ53ïŒ329ïŒ1975ïŒã«èšèŒãããŠã
ãD.ããŠãŒãã€ã€ãŒæ°çã®è«æã«é瀺ãããŠã
ãæ¹æ³ïŒãã®æ¹æ³ã¯U.ãŠã«ãããŒã°æ°çã®ç±³åœ
ç¹èš±ç¬¬4067775å·ã«ãé瀺ãããŠããïŒãããã
äžèšè«æããã³ç¹èš±ã«ã¯ãMMããã³MBã¯MM
æè¡æž ã«ãã€ãŠå®éçã«æ²æ®¿ããããšãè¿°ã¹ãã
ãŠãããåæ§ã«ãBBããã³MBã¯BBæè¡æž ã«ã
ã€ãŠå®éçã«æ²æ®¿ããããšãè¿°ã¹ãããŠãããã
ãã«ãäžèšè«æããã³ç¹èš±ã®è¡æž è©Šæäžã«ã¯BB
ã¯ååšããªãããšãè¿°ã¹ãããŠãããåŸã€ãŠãäž
èšè«æããã³ç¹èš±ã®æ¹æ³ã«ãããŠã¯ããŸãCK掻
æ§åºŠã®ç·èšãåæãããã次ãã§BBæè¡æž ã«ã
ãæ²æ®¿ã®åŸã®äžæŸã¿æ¶²äžã«æ®çããŠãã掻æ§åºŠã
åæãããããã®ããã«ããŠæ±ããïŒã€ã®å€ã®å·®
ãè¡æž è©Šæäžã®MB掻æ§åºŠãè¡šãããã®ã§ãããš
ããŠããã CKã€ãœé µçŽ ã®æŸå°ç·å ç«åæããŸãç¥ãããŠ
ãããClinïŒChimïŒActaïŒ79ïŒ107ïŒ1977ïŒã«èš
èŒãããŠããD.ããŠãŒãã€ã€ãŒæ°çã®è«æã«ã
ãã°ãMBããã³BBäžã®ãµããŠãããã125
ã§æšèä»ãããBBæè¡æž ãçšããè€æäœ
ïŒdoubleâantibodyïŒæŸå°ç·å ç«åæã«ãã€ãŠå®
éãããããŸãã 125ã§æšèä»ãããCKã€ãœ
é µçŽ ã䜿çšããMBã®æ®æç眮ææŸå°ç·å ç«åæ
ãR.ãããŒãæ°çã«ãã€ãŠClinïŒChimïŒActaïŒ
83ïŒ141ïŒ1978ïŒã«å ±åããããããã«ã 125ã§
æšèä»ãããã€ãœé µçŽ ã䜿çšããMMããã³BB
ã«ã€ããŠè€æäœæŸå°ç·å ç«åæãA.C.ãŽã¢ã³
ã¹ã¿ã€ã«ãã²ã æ°çã«ãã€ãŠClinïŒChemïŒïŒ24ïŒ
414ïŒ1978ïŒã«ããŸãM.H.ããŽã¢ã€ã°æ°çã«ãã€
ãŠClinïŒChemïŒïŒ24ïŒ422ïŒ1978ïŒã«å ±åãããã ããã«ãCKã€ãœé µçŽ ã®å®éã®ããã®å ç«åžç
å€æ³ãJ.ããªã¢ãŒãæ°çã«ãã€ãŠArchïŒ
BiochemïŒBiophysïŒïŒ191ïŒ90ïŒ1978ïŒã«å ±åã
ããããã®æ¹æ³ã«ãããŠã¯ããŸãçŽç²ãªMMãã
ã³BBæè¡æž ã調補ãããåæè¡æž ã¯ããã¢ã·ã¢
ã³ã§æŽ»æ§åããã»ãã¢ããŒãº4BïŒSepharose4BïŒ
ã«å¥ã ã«çµåããïŒçš®é¡ã®å ç«åžçå€ã調補ãã
ãã次ã«è©Šæäžã®CKã€ãœé µçŽ ã®æŽ»æ§åºŠã®ç·èšã
åæãããããã®åŸãè©Šæã®ã¢ãªã³ãŒããåå ç«
åžçå€ã«ã©ã ã«éãããããªãŒã®ã€ãœé µçŽ ãåã«
ã©ã ããæŽãèœãããåã«ã©ã ã«ã€ããŠããªãŒã®
ã€ãœé µçŽ ã®æŽ»æ§åºŠãåæããããMMæè¡æž ãå«
ãã«ã©ã ããæ±ããããããªãŒã®ã€ãœé µçŽ ã®æŽ»æ§
床ã¯BB掻æ§åºŠãè¡šãããBBæè¡æž ãå«ãã«ã©
ã ããæ±ããããããªãŒã®ã€ãœé µçŽ ã®æŽ»æ§åºŠã¯
MM掻æ§åºŠãè¡šãããåŸã€ãŠãMB掻æ§åºŠã¯å ã«
æ±ããè©Šæäžã®CKã€ãœé µçŽ ã®æŽ»æ§åºŠã®ç·èšãã
MM掻æ§åºŠããã³BB掻æ§åºŠãåŒãããšã«ãã€ãŠ
æ±ããããã 以äžè¿°ã¹ãåŸæ¥ã®æ¹æ³ã®ãããã«ãããŠããã€
ãœé µçŽ âæäœé¯åäœã®ã€ãœé µçŽ 掻æ§åºŠã¯ååšããª
ããšä»®å®ãããããããããã¯ååšããªãããšã
ç¥ãããŠãããå¿è«ãããã¯æ¢ç¥ã®æäœã«ãã
CKã€ãœé µçŽ ã®äžæŽ»æ§åã«ççŸãããã®ã§ã¯ãªãã
äžè¿°ã«ã€ããŠã¯ãäŸãã°ãã¢ã«ããã㯠ãã¬ã¹
瀟ïŒAcademic PressïŒNew YorkïŒ1977幎åºç
ã®C.A.ãŠã€ãªã¢ã ãºããã³M.W.ããšã€ã¹æ°å ±è
ãå ç«åŠããã³å ç«ååŠã«ãããæ¹æ³ãã第ïŒå·»ã
第317é ïŒããŒã¬ã¢ã³ ãã¬ã¹ç€Ÿãã·ã³ããžãŠã
åºçéšïŒPergamon PressïŒSymposium
Publications DivisionïŒOxfordïŒ1967幎åºçã®
ã»ã·ãããŒæ°èãçç©åŠç掻æ§ååã«å¯Ÿããæ
äœãïŒ1965幎ïŒæ21ã24æ¥ã«ãŠã€ãŒã³ã§éå¬ãã
ããšãŒããçç©ååŠäŒé£çã®ç¬¬ïŒåéäŒã®äŒå ±ã§
ããïŒã第ïŒå·»ã第87é ïŒAnnïŒïŒ®ïŒïŒ¹ïŒAcadïŒ
SciïŒïŒ103(2)ïŒ500ïŒ1963ïŒã«èšèŒãããŠããB.ã·
ãããŒæ°ã®è«æïŒããã³ãžãšã³ãŠã€ãªãŒã»ã¢ã³
ãã»ãµã³ãºç€ŸïŒJohn WileyïŒSonsïŒNew
YorkïŒ1977幎åºçã®M.R.J.ãµã«ãã³æ°èãé µçŽ
ããã³ãã®æäœã®å ç«ååŠãã第104é ãåç §ãã
ããã ãã®ããã«ãæäœâã€ãœé µçŽ é¯åäœã®CKã€ãœ
é µçŽ æŽ»æ§åºŠãåæããããšã«ãã€ãŠCKã€ãœé µçŽ
ã®ååšãç«èšŒããããšããå ±åã¯åŸæ¥ç¥ãããŠã
ãªãã åŸã€ãŠãæ¬çºæã®ç®çã¯CKã€ãœé µçŽ ã®åææ¹
æ³ãæäŸããããšã«ããã æ¬çºæã®å¥ã®ç®çã¯åºå®æäœâã€ãœé µçŽ é¯åäœ
ã«ãã€ãŠCKã€ãœé µçŽ ãåæããããã®æ¹æ³ãæ
äŸããããšã«ããã æ¬çºæã®ããã«å¥ã®ç®çã¯åæå¯èœãªã€ãœé µçŽ
掻æ§åºŠãä¿æããŠããåºå®æäœâã€ãœé µçŽ é¯åäœ
ã«ãã€ãŠCKã€ãœé µçŽ ãåæããããã®æ¹æ³ãæ
äŸããããšã«ããã ãããç®çããã³ãã®ä»ã®ç®çã¯æ¬æ现æžãã
æããã«ãªãã§ãããã å šãæå€ã«ããç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãªåº
å®æäœã¯ãã®ã€ãœé µçŽ ãšçµåããŠãåæå¯èœãªã€
ãœé µçŽ 掻æ§åºŠãä¿æããŠããåºå®æäœâã€ãœé µçŽ
é¯åäœãçæããããšãããªãã¡ãã€ãœé µçŽ 掻æ§
床ãå®å šã«é»å®³ããããšãªãåºå®æäœâã€ãœé µçŽ
é¯åäœãçæããããšãèŠåºãããã åŸã€ãŠãæ¬çºæã¯ç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãª
åºå®æäœã液äœè©Šæã«æ¥è§Šããã次ãã§äžèšåºå®
æäœãããã¯çããåºå®æäœâã€ãœé µçŽ é¯åäœã
ããã¯äžèšåºå®æäœãšäžèšåºå®æäœâã€ãœé µçŽ é¯
åäœã®æ··åç©ãåé¢ãããããåŸåé¢ããç©è³ªã®
ã€ãœé µçŽ 掻æ§åºŠãåæããããšãããªã液äœè©Šæ
äžã®CKã€ãœé µçŽ ã®åææ¹æ³ãæäŸãããã®ã§ã
ãã ãŸããæ¬çºæ㯠 液äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³ãŒã
ããç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãªåºå®æäœãšæ··
åãã  äžèšã¹ãããã§åŸãããæ··åç©ãå¹é€ãã  äžèšã¹ãããã§åŸãããå¹é€æ··åç©ããäž
èšåºå®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ
é¯åäœãããã¯äžèšåºå®æäœãšäžèšåºå®æäœâ
ã€ãœé µçŽ é¯åäœã®æ··åç©ãåé¢ãããããåŸ ïŒ€ äžèšã¹ãããã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻
æ§åºŠãåæãã ããšãããªã液äœè©Šæäžã®CKã€ãœé µçŽ ã®åææ¹
æ³ãæäŸãããã®ã§ããã 人éã®è¡æž äžã®åçš®CKã€ãœé µçŽ ãå®æ§çã«ã
ããã¯å®éçã«åæããããšã¯ãå¿çæ¢å¡ãå¿è
é害ãé²è¡æ§çç°æ é€çãç®èççãããªã°ãã
ã³å°¿çã䌎ãçŸç ãæªæ§é«ç±çã®çš®ã ã®ç æ°ã蚺
æããã®ã«æå¹ã§ããã æ¬æ现æžã§äœ¿çšããã液äœè©Šæããšããçšèª
ã¯ãæ¬æ¥æ¶²äœã§ããè©Šæãšè©Šææ¡åã®åŸæ¶²äœã®ç¶
æ ã«å€æãããè©Šæã®ãããããæå³ãããåŸã€
ãŠã液äœè©Šæã¯äººäœçµç¹ã®æœåºç©ã§ãã€ãŠããã
ãã人éã®è¡æž ãèžè液ãå°¿ãèæ€æ¶²ãããã¯ç²Ÿ
液ã§ãã€ãŠããããå®éã«ã¯ã液äœè©Šæã¯ã»ãšã
ã©ã®å Žåè¡æž ã§ããã 液äœè©Šæäžã®CKã€ãœé µçŽ 掻æ§åºŠã®ç·èšãåæ
ããã®ãæãŸãããããããã¯å¿ èŠã§ããå Žåã
ããã以äžã«è¿°ã¹ãããã«ãæ¬çºæã¯ãã®ãããª
åæã®ããã®æ¹æ³ãæäŸãããã®ã§ãããããã
ãªããã液äœè©Šæäžã®CKã€ãœé µçŽ 掻æ§åºŠã®ç·èš
ã®åæã¯æ¢ç¥ã®æ¹æ³ã«ãã€ãŠè¡ãªã€ãŠãããã
CKã€ãœé µçŽ 掻æ§åºŠã®ç·èšã®åæã¯å Žåã«å¿ããŠ
æ¬çºæã®æ¹æ³ãè¡ãªãåããããã¯æ¬çºæã®æ¹æ³
ãè¡ã€ãŠããéããããã¯ãæ¬çºæã®æ¹æ³ãè¡ãª
ã€ãåŸè¡ãªãããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã¹ãããã¯æ¶²äœè©Šæããã
ã¯ãã®ã¢ãªã³ãŒããç¹å®ã®CKã€ãœé µçŽ ã«ç¹ç°ãª
åºå®æäœãšæ··åããããšãããªããäžè¬ã«ãç¹å®
ã®CKã€ãœé µçŽ ã«ç¹ç°ãªæäœã¯æ¢ç¥ã®æ¹æ³ã«åŸã€
ãŠèª¿è£œããããããããªãããäžè¬ã«åŸãããæ
è¡æž ãããã«åŠçããŠç²Ÿè£œæäœãšããå¿ èŠã¯ãª
ãã䟿å®äžåºå®æäœã¯æè¡æž ããçŽæ¥èª¿è£œãã
ããåŸã€ãŠãåºå®æäœã¯å¿ ç¶çã«äŸãã°ã°ãããª
ã³ã®ãããªæ¬çºæã®æ¹æ³ã«ã¯é¢äžããªãçš®ã ã®ã¿
ã€ãã®åºå®ã¿ã³ãã¯è³ªãšå ±åããŠãããæè¡æž ã
ãçŽæ¥èª¿è£œãããåºå®æäœã¯ã€ãœé µçŽ 掻æ§åºŠã®å
äœåœãã®å¿ èŠéã粟補æè¡æž ãã調補ãããåºå®
æäœãããå€ããªãããåºå®æäœã¯çŽåºŠãé«ãã
ã®ã§ããå¿ èŠã¯ãªããåŸã€ãŠãæ¬æ现æžã§äœ¿çšã
ããåºå®æäœããšããçšèªã¯ãç¹å®ã®çŽåºŠã®åºå®
æäœãæå³ãããã®ã§ã¯ãªãã æäœã®åºå®ã¯æ¢ç¥ã®æ¹æ³ã«åŸã€ãŠè¡ãªãããã
æ害ãªäœçšãé¿ãããããªãã°æ äœããã³åºå®æ¹
æ³ã¯ããããéèŠãªãã®ã§ã¯ãªããåŸã€ãŠãæ äœ
ã¯ææ©ç©ãããã¯ç¡æ©ç©ã®ãããã§ãã€ãŠããã
ããå€åæ§ç©è³ªãããã¯éå€åæ§ç©è³ªã®ãããã§
ãã€ãŠããããããŸããããªã圢ç¶ã®ãã®ã§ãã€
ãŠããããæ äœã¯åŸ®ç²ããç²ãç²åãŸã§ã®ç²åç¶
ç©è³ªã§ãã€ãŠãããããå¹³æ ãªãŸãã¯æ¹Ÿæ²ããã·
ãŒãããã¬ããã®ãããªé£ç¶çãªé 圢åãããã
ã¯ç©åœ¢ç¶ãŸãã¯åçç¶ã®ããŠãŒããè€éãªã¢ããª
ã¹ã®ãããªç«äœçç©åã§ãã€ãŠãããã䟿å©ã§ã
ãã®ã§ã»ãšãã©ã®å Žåæ äœãšããŠäŸãã°ç±³åœç¯©èŠ
æ Œã§çŽ20ä¹è³çŽ100ã¡ãã·ãŠã®æ¯èŒç埮现ãªç²å
ç¶ç©è³ªãçšããããã é©åœãªææ©æ äœã®äŸãšããŠãç¹ã«ããªïŒãšãã¬
ã³ãã¬ãã¿ã¬ãŒãïŒã®ãããªããªãšã¹ãã«ïŒãã€
ãã³ïŒããã³ãã€ãã³6.6ã®ãããªããªã¢ããïŒ
ããªã¢ã¯ãªã¬ãŒãïŒããªã¡ã¿ã¯ãªã¬ãŒãïŒã¢ã¬ã
ãŒã¹ã²ã«ïŒããã¹ãã©ã³ã²ã«ïŒããªãšãã¬ã³ãã
ãªãããã¬ã³ãããªããã³ããã³ããªãã¿ãžãšã³
ã®ãããªããªãªã¬ãã€ã³ïŒããªã¹ãã¬ã³ïŒããª
ïŒããã«ã¯ãã©ã€ãïŒïŒããªïŒãããªãã³ã¯ãã©ã€
ãïŒçãæããããã ç¡æ©æ äœã¯ãçªè³ªç©è³ªãšéçªè³ªéå±é žåç©ã«å
ãããããçªè³ªæ äœã®äŸãšããŠãã¬ã©ã¹ãã·ãª
ã«ãçªç°ç³ããã³ããã€ããè«éç³çãæããã
ããéçªè³ªéå±é žåç©æ äœã®äŸãšããŠãç¹ã«ã¢ã«
ãããå°æ¶ç³ãçç°ç³ãé žåããã±ã«ããã¿ã
ã¢ããžã«ã³ãã¢çãæãããããç¡æ©æ äœã®æ¹ã
ãã奜ãŸãããç¡æ©æ äœã®äžã§ãçªè³ªç©è³ªãç¹ã«
奜ãŸãããæã奜ãŸããæ äœã¯ã·ãªã«ãšã¬ã©ã¹ã§
ãããæ äœã®åäœå®¹ç©ãããã¯åäœééåœãã®æ
äœã®éãå€ããªãããã«ãæ äœã¯å€å質ã§ããã®
ã奜ãŸããã äžè¬ã«ãæäœã®åºå®ã¯ç°¡åãªåžçããååŠççµ
åãŸã§ã®æ¢ç¥ã®æ¹æ³ã®ãããã«ãã€ãŠè¡ãªã€ãŠã
ãããåšç¥ã®ããã«ãåžçã¯äžè¬ã«åºå®ãããæ
äœã®æ°Žæº¶æ¶²ïŒæè¡æž ïŒãæã¿ã®ïŒãããã¯æ倧
ã®ïŒåºå®åºŠãéæãããã®ã«å åãªæéæ äœã«æ¥
觊ãããããšãããªããååŠççµåã¯ãäžè¬ã«æ
äœãïŒçš®ãããã¯ïŒçš®ä»¥äžã®ååç©ã§åŠçããã
ã®åŸåŠçããæ äœãæäœã®æ°Žæº¶æ¶²ã«æ¥è§Šãããã
ãšãããªããæ äœãç¹ã«ç¡æ©æ äœãåŠçããã®ã«
çšããããååç©ã®äŸãšããŠãâãžã¢ãã·ãžã³
ïŒç±³åœç¹èš±ç¬¬3983000å·åç §ïŒãã€ãœã·ã¢ããŒãã
ãªããŒïŒç±³åœç¹èš±ç¬¬4071409å·åç §ïŒãã·ã©ã³ïŒç±³
åœç¹èš±ç¬¬3519538å·åç §ïŒçãæãããããæ äœ
ãåŠçããã®ã«äœ¿çšããååç©ã«ã€ããŠã¯ãç±³åœ
ç¹èš±ç¬¬3930951ããã³3933589å·ããŸãåç §ããã
ãã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã®ã¹ãããã¯ç¬¬ïŒã®ã¹ãã
ãã§åŸãããæ··åç©ãå¹é€ããããšãããªããäž
è¬ã«å¹é€ã¯çŽïŒâä¹è³çŽ40âã®æž©åºŠã§è¡ãªãã
ããç¹ã«å¥œãŸããå¹é€æž©åºŠã¯37âã§ãããå¹é€æ
éã¯éé¢ãªãã®ã§ã¯ãªããäžè¬ã«çŽ0.5æéä¹è³
çŽïŒæéã§ãããããããªãããã»ãšãã©ã®å Žå
å¹é€æéã¯äŸ¿å®äžïŒæé以å ãšãããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã®ã¹ãããã«ãããŠã¯ãåº
å®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ é¯åäœ
ãããã¯ãããã®æ··åç©ã第ïŒã¹ãããå¹é€æ··å
ç©ããåé¢ãããããã®åé¢ã¯é å¿åé¢ãæ¿Ÿéã®
ãããªæ¢ç¥ã®åé¢æ¹æ³ã®ãããã«ãã€ãŠè¡ãªã€ãŠ
ãããããé å¿åé¢ãç¹ã«æå¹ã§ãããåŸã€ãŠé
å¿åé¢ãç¹ã«å¥œãŸããã æ¬çºæã®æ¹æ³ã®ç¬¬ïŒã®ã¹ãããã¯ç¬¬ïŒã®ã¹ãã
ãã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻æ§åºŠãåæããã
ãšãããªãããã®åæã¯æ¢ç¥ã®æ¹æ³ã®ãããã«ã
ã€ãŠè¡ãªã€ãŠããããããŸãå®æ§çã«è¡ãªã€ãŠã
ãããããããã¯å®éçã«è¡ãªã€ãŠãããã CKã€ãœé µçŽ ã¯äžèšã®åå¿ã®è§ŠåªãšããŠäœçšã
ãããšã¯åšç¥ã§ããã ïŒäœããäžèšADPããã³ATPã¯ããããã¢ã
ãã·ã³5â²âäºçé žããã³ã¢ããã·ã³5â²âäžçé žã
è¡šãããïŒ ããã«ãäžèšã®åå¿ããŸãåšç¥ã§ããã äœãäžèšHKã¯ãããœãããŒãŒãè¡šããã
NAD+ããã³NADHã¯ããããé žåããã³éå
ç¶æ ã®ãã³ãã³ã¢ããã¢ããã³ãžãã¯ã¬ãªããã
è¡šããããŸãâïŒâPDHã¯ã°ã«ã³ãŒã¹âïŒâ
çé žããããã²ããŒãŒãè¡šãããïŒ åŸã€ãŠãCKã€ãœé µçŽ ãåæããã®ã«ç¹ã«æå¹
ã§ããåžè²©ã®åºè³ªã¯ã¯ã¬ã¢ãã³çé žãADPãã°
ã«ã³ãŒã¹ãNAD+ããããœãããŒãŒããã³ã°ã«ã³
ãŒã¹âïŒâçé žããããã²ããŒãŒãå«ãã§ããã
ãã®ãããªåºè³ªã䜿çšããããšã«ãã€ãŠNADH
ã340nmã§ã®åå 枬å æ³ãããã¯è¢å åææ³ã«ã
ã€ãŠå®¹æã«æ€åºããªãã¡åæããããšãã§ããã
äžèšåºè³ªã®åžè²©åã®äžäŸã¯ã¯ãŒã·ã³ãã³ãã€ã¢ã°
ãã¹ãã€ãã¯ã¹ç€ŸïŒWorthington DiagnosticsïŒ
FreeholdïŒNew Jersey 07728ïŒã®ã¹ã¿ããã¶ã€
ã ïŒSTATZYMEãç»é²åæšïŒCRKnâïŒã§ã
ããäžèšNAD+ããã³ïŒ§âïŒâPDHã¯ãããã
NADP+ããã³NADP+ã«ç¹ç°ãªé µçŽ ã«çœ®ãæã
ãããŠããŠãããã å¿è«ãä»ã®åºè³ªãçšããããšãå¯èœã§ããã
NADH以å€ã®ç©è³ªãæ€åºããããšãå¯èœã§ããã
ããã«ãNADHã®ååšã¯ä»ã®æ¹æ³ã«ãã€ãŠãæ€
åºããããšãã§ãããäŸãã°ãNADHã«ãã€ãŠ
éå ããããææãåºè³ªæº¶æ¶²ã«å«ãŸããããšã«ã
ããåå å 床èšã䜿çšããæ¯è²æ³ã«ãã€ãŠ
NADHãåæããããšãã§ãããäžèšææã®äŸ
ãšããŠãâã¢ã€ãªããããããã©ãŸãªãŠã ãã€
ãªã¬ãããããããã«âããã©ãŸãªãŠã ã¯ãã©ã€
ããããã¯ããšããžã³ã¡ããµã«ããšãŒããšçµåã
ãä»ã®é©åœãªããã©ãŸãªãŠã å¡©ã®ãããªNADH
çµåæ§æ¯è²ææ調åç©ãæããããããŸããäžèš
âïŒâPDHã觊åªãšããåå¿ããã³äžèšHK
ã觊åªãšããåå¿ã¯ãã¯ã¬ã¢ãã³ã®ãããªäžèš
CKã觊åªãšããåå¿ã®çæç©ãšçµåããè©Šè¬ã
çšããããšã«ãã€ãŠåé¿ããããšãã§ãããäžèš
è©Šè¬ãšããŠãαâããããŒã«ãšãžã¢ã»ãã«ã䜵çš
ãããããã®ïŒã€ã®ååç©ã¯ã¯ã¬ã¢ãã³ãšçµåã
ãŠãã³ã¯è²ã®é¯åäœãçæããã çšããããåææ¹æ³ã«ããããããåŸãããã
ãŒã¿ã¯åšç¥ã®æ¹æ³ã«åŸã€ãŠæ€éç·ãšæ¯èŒãããã
ãã«ãã€ãŠCKã€ãœé µçŽ ãå®éãããã æ¬çºæã®æ¹æ³ã«ãã€ãŠCKã€ãœé µçŽ 掻æ§åºŠã®ç·
èšãåæããã®ã«ã¯ãMMããã³BBã€ãœé µçŽ ã
ãããã«ç¹ç°ãªåºå®æäœã䜿çšããŠãåäžæ¶²äœè©Š
æã«ã€ããŠæ¬çºæã®æ¹æ³ãè¡ãªãããšãå¿ èŠãªã
ãã§ãããå¿è«ãäžããããè©Šæã«ã€ããŠãŸã
MMããã³BBã®ããããäžæ¹ã«ç¹ç°ãªåºå®æäœ
ã䜿çšããŠæ¬çºæã®æ¹æ³ãè¡ãªããã次ã«åäžè©Š
æã«ã€ããŠMMããã³BBã®ããäžæ¹ã®ç¹ç°ãªåº
å®æäœã䜿çšããŠæ¬çºæã®æ¹æ³ãè¡ãªããããã
ãããªãããMMããã³BBããããã«ç¹ç°ãªåº
å®æäœãæ··åããåŸãããæ··åç©ã䜿çšããŠæ¬çº
æã®æ¹æ³ãè¡ãªãã®ããã䟿å©ã§ããã 次ã«å®æœäŸã«ãã€ãŠæ¬çºæã説æããã å®æœäŸ çã®çèããMMåã®CKã€ãœé µçŽ ãåé¢ãã
ArchïŒBiochemïŒBiophysïŒïŒ150ïŒ648ïŒ1972ïŒ
ã«èšèŒãããŠããH.J.ããŠãŒãã«æ°çã®è«æã®æ¹
æ³ã«åŸã€ãŠç²Ÿè£œããã次ã«ãã®ã€ãœé µçŽ ã«å¯Ÿãã
æäœãæšæºæ³ã«åŸã€ãŠãŠãµã®äžã§çæãããåºå®
æè¡æž ïŒåºå®æäœãIMAïŒã¯ãŠã€ãŒã¿ã«ããã³
ãã€ã«ããŒãæ°ã®æ¹æ³ã«åŸã€ãŠèª¿è£œããïŒã¢ã«ã
ããã¯ãã¬ã¹ç€Ÿ1974幎åºçã®B.ãžã€ã³ããŒãã
ã³M.ãŠã€ã«ããšãã¯æ°å ±èãé µçŽ åŠã«ãããæ¹
æ³ãã第34Bå·»ã第59ã72é åç §ã®ããšïŒããã®å Ž
åãæ äœãšããŠå¹³åçŽåŸã550â«ã®å¶åŸ¡ããã现
åãæããå¹³åç²åãµã€ãºãïŒãã¯ãã³ã®ã¬ã©ã¹
ã䜿çšãããã®ã¬ã©ã¹ãšæè¡æž ã®å²åãã¬ã©ã¹ïŒ
ïœã«å¯ŸããŠæè¡æž ïŒmlãšããããã®åºå®æäœã®èª¿
補ãç°¡åã«èª¬æãããšããŸãäžèšã¬ã©ã¹ãïŒïŒ ç¡
é žæº¶æ¶²äžã§æž æµã«ããæŽæµãPH3.45ã®10ïŒ Î³âã¢
ãããããã«ããªãšããã·ã·ã©ã³æ°Žæº¶æ¶²ã§åŠçã
ããåŸãããã·ã©ã³åã¬ã©ã¹ãæå»å€ãšããŠããª
ãšãã«ã¢ãã³ã10容éïŒ å«ãã¯ãããã«ã äžã§ïŒ°
âããããã³ãŸã€ã«ã¯ãã©ã€ããšåå¿ãããã次
ã«ïŒ°âããããã³ãŸã€ã«ã¢ããã¢ã«ãã«ãçãã
ã¬ã©ã¹ã10ïŒ ãžããªã³é žãããªãŠã 氎溶液ã§åŠç
ããŠãããåºãéå ãããåŸãããâã¢ããã
ã³ãŸã€ã«ã¢ããã¢ã«ãã«ãçããã¬ã©ã¹ãå¡©é žãš
äºç¡é žãããªãŠã ããçããããäºç¡é žã§ãžã¢ãŸ
åããããžã¢ãŸåçæç©ãæŽæµããPHïŒãïŒã®æ
è¡æž äžã«å ¥ãããåŸãããåºå®æäœãé å¿åé¢ã«
ãã€ãŠåé¢ããæŽæµãã0.01Mã®çé žå¡©ãç·©è¡å€
ãšããPH7.4ã®å¡©æ°ŽïŒç·©è¡å¡©æ°ŽïŒäžã«ãã®ç·©è¡å¡©
æ°ŽïŒmlã«ã€ãIMA10mgã®å²åã§æžæ¿ããããã
ã®ããã«ããŠåŸãIMAã¯ã¬ã©ã¹100mgã«ã€ã32mg
ã®ã¿ã³ãã¯è³ªãå«ãã§ããã æ¢ç¥ã®æ¿åºŠã®äžèšç²Ÿè£œMMã€ãœé µçŽ ãå«æãã
溶液0.5mlã«äžèšIMAæžæ¿æ¶²0.5mlãæ·»å ãããåŸ
ãããæ··åç©ã37âã§30åéå¹é€ããããã®åŸæ··
åç©ãé å¿åé¢ããIMAãšIMAâMMé¯åäœã®
æ··åç©ã®å¡ãåŸãããã®å¡ãåã³PH7.4ã®ç·©è¡å¡©
æ°Žäžã«æžæ¿ãããé å¿åé¢ã«ãã€ãŠåæ²æ®¿ãããŠ
IMAãšç¹ç°çã«çµåããªãé µçŽ ãããã¯ãã®ä»
ã®ã¿ã³ãã¯è³ªãé€å»ããããã®åŸå¡ãã¹ã¿ããã¶
ã€ã CPKnâïŒã1.0mläžã«æžæ¿ããã宀枩ïŒ25
âïŒã§å¹é€ããããã®å Žåãå¥ã ã®è©ŠæãïŒïŒ
ïŒïŒ10ããã³20åéå¹é€ãããå¹é€ã®åŸãæ··åç©
ãé å¿åé¢ããåŸãããäžæŸã¿æ¶²ã®340nmã«ãã
ãå åŠæ¿åºŠãåå å 床èšã«ãã€ãŠæž¬å®ãããåæ¢
ç¥ã®æ¿åºŠã«ã€ããŠãäžèšåå¹é€æéã«ã€ããŠã®æž¬
å®çµæãå¹³åããŠïŒåéåœãã®â³O.D.ãæ±ããã
ãããã®å Žåããã©ã³ã¯è©Šéšãè¡ãªãã枬å®å€ã
ããã©ã³ã¯å€ãåŒããŠäžèšã®è¡šã«ç€ºããããã©ã³
ã¯è£æ£å€ãåŸãã ãè¡šã äžè¡šã®ããŒã¿ãçšããŠãåšç¥ã®æ¹æ³ã«åŸã€ãŠæ€
éç·ãäœè£œããã MMã€ãœé µçŽ 溶液ã®ä»£ããã«çã®è³ããåé¢ã
ãBBã€ãœé µçŽ ã®æº¶æ¶²ãçšããããšä»¥å€ã¯äžè¿°ãš
åæ§ã«ããŠäžèšã®ããŒã¿ãåŸãã ãè¡šã ãã®ããã«ã䜿çšããIMAã§ã¯å€å°ã®äº€åå
å¿ãèŠããããã®äº€ååå¿ã¯çŽ15ïŒ ã§ãã€ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ç¹å®ã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã«ç¹ç°ãª
åºå®æäœã液äœè©Šæã«æ¥è§Šããã次ãã§äžèšåºå®
æäœãããã¯çããåºå®æäœâã€ãœé µçŽ é¯åäœã
ããã¯äžèšåºå®æäœãšäžèšåºå®æäœâã€ãœé µçŽ é¯
åäœã®æ··åç©ãåé¢ãããããåŸåé¢ããç©è³ªã®
ã€ãœé µçŽ 掻æ§åºŠãå®æ§çã«åæããããšãããªã
液äœè©Šæäžã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã®åæ
æ¹æ³ã ïŒ äžèšåºå®æäœã®æ äœãç²åç¶ç¡æ©æ äœã§ãã
ããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å
ææ¹æ³ã ïŒ äžèšæ äœãçªè³ªç©è³ªã§ããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹æ³ã ïŒ äžèšæ äœãå¶åŸ¡ããã现åãæããã¬ã©ã¹ã§
ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®åææ¹æ³ã ïŒ äžèšæ¶²äœè©Šæã人éã®è¡æž ã§ããããšãç¹åŸŽ
ãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹æ³ã ïŒ ïŒ¡ 液äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³ãŒ
ãããç¹å®ã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã«ç¹
ç°ãªåºå®æäœã®å°ãªããšãïŒçš®ãšæ··åãã  äžèšã¹ãããã§åŸãããæ··åç©ãå¹é€ãã  äžèšã¹ãããã§åŸãããå¹é€æ··åç©ããäž
èšåºå®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ
é¯åäœãããã¯äžèšåºå®æäœãšäžèšåºå®æäœâ
ã€ãœé µçŽ é¯åäœã®æ··åç©ãåé¢ãããããåŸ ïŒ€ äžèšã¹ãããã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻
æ§åºŠãå®éçã«åæãã ããšãããªã液äœè©Šæäžã®ã¯ã¬ã¢ãã³ãããŒãŒã€
ãœé µçŽ ã®åææ¹æ³ã ïŒ äžèšåºå®æäœã®æ äœãç²åç¶ç¡æ©æ äœã§ãã
ããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å
ææ¹æ³ã ïŒ äžèšæ äœãçªè³ªç©è³ªã§ããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹æ³ã ïŒ äžèšæ äœãå¶åŸ¡ããã现åãæããã¬ã©ã¹ã§
ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®åææ¹æ³ã ïŒïŒ äžèšæ¶²äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³
ãŒãããBBåã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã«
ç¹ç°ãªåºå®æäœã®ã¿ãšæ··åããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹æ³ã ïŒïŒ äžèšæ¶²äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³
ãŒãããMMåã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã«
ç¹ç°ãªåºå®æäœã®ã¿ãšæ··åããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹æ³ã ïŒïŒ äžèšæ¶²äœè©Šæã人éã®è¡æž ã§ããããšãç¹
城ãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹æ³ã ïŒïŒ äžèšæ¶²äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³
ãŒãããMMåã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã«
ç¹ç°ãªåºå®æäœãšBBåã®ã¯ã¬ã¢ãã³ãããŒãŒã€
ãœé µçŽ ã«ç¹ç°ãªåºå®æäœã®æ··åç©ã«æ··åããããš
ãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åææ¹
æ³ã ïŒïŒ  液äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³
ãŒãããMMåã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ
ã«ç¹ç°ãªåºå®æäœãšBBåã®ã¯ã¬ã¢ãã³ãããŒ
ãŒã€ãœé µçŽ ã«ç¹ç°ãªåºå®æäœã®ãã¡ã®ãããã
äžæ¹ãšæ··åãã  äžèšã¹ãããã§åŸãããæ··åç©ãå¹é€ãã  äžèšã¹ãããã§åŸãããå¹é€æ··åç©ããäž
èšåºå®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ
é¯åäœãããã¯äžèšåºå®æäœãšäžèšåºå®æäœâ
ã€ãœé µçŽ é¯åäœã®æ··åç©ãåé¢ãããããåŸ ïŒ€ äžèšã¹ãããã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻
æ§åºŠãåæãã次ã㧠 äžèšæ¶²äœè©Šæãããã¯è©²æ¶²äœè©Šæã®ã¢ãªã³ãŒ
ãããMMåã®ã¯ã¬ã¢ãã³ãããŒãŒã€ãœé µçŽ ã«
ç¹ç°ãªåºå®æäœãšBBåã®ã¯ã¬ã¢ãã³ãããŒãŒ
ã€ãœé µçŽ ã«ç¹ç°ãªåºå®æäœã®ãã¡ã®äžèšã¹ãã
ãã§äœ¿çšããªãã€ãæ¹ã®åºå®æäœãšæ··åãã  äžèšã¹ãããã§åŸãããæ··åç©ãå¹é€ãã  äžèšã¹ãããã§åŸãããå¹é€æ··åç©ããäž
èšåºå®æäœãããã¯çããåºå®æäœâã€ãœé µçŽ
é¯åäœãããã¯äžèšåºå®æäœãšäžèšåºå®æäœâ
ã€ãœé µçŽ é¯åäœã®æ··åç©ãåé¢ãããããåŸ ïŒš äžèšã¹ãããã§åŸãããç©è³ªã®ã€ãœé µçŽ 掻
æ§åºŠãåæãã ããšãããªã液äœè©Šæäžã®ã¯ã¬ã¢ãã³ãããŒãŒã€
ãœé µçŽ ã®åææ¹æ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/014,315 US4260678A (en) | 1979-02-23 | 1979-02-23 | Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55107958A JPS55107958A (en) | 1980-08-19 |
| JPS6331741B2 true JPS6331741B2 (ja) | 1988-06-27 |
Family
ID=21764738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1235680A Granted JPS55107958A (en) | 1979-02-23 | 1980-02-04 | Method of analyzing creatine kinase isooenzyme |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4260678A (ja) |
| JP (1) | JPS55107958A (ja) |
| AU (1) | AU529444B2 (ja) |
| DE (1) | DE3006118A1 (ja) |
| FR (1) | FR2449895A1 (ja) |
| GB (1) | GB2043894B (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2952478A1 (de) * | 1979-12-27 | 1981-07-30 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren und mittel zur immunologischen bestimmung von enzymen |
| US4353982A (en) * | 1980-04-10 | 1982-10-12 | Hoffmann-La Roche Inc. | Immunochemical assay for creatine kinase-MB isoenzyme |
| GB2078953B (en) * | 1980-06-30 | 1984-06-13 | Int Immunoassay Lab Inc | Two site cross-reaction immunometric sandwich assay method |
| US5009997A (en) * | 1980-06-30 | 1991-04-23 | Shah Vipin D | Two site cross-reaction immunometric sandwich assay method |
| US5009996A (en) * | 1980-06-30 | 1991-04-23 | International Immunoassay Laboratories, Inc. | Two site cross-reaction immunometric sandwich assay method |
| US4387160A (en) * | 1981-02-17 | 1983-06-07 | Hoffmann-La Roche Inc. | Immunochemical assay for creatine kinase-MB isoenzyme |
| CA1185525A (en) * | 1981-06-22 | 1985-04-16 | Hans J. Hager | Immunochemical assay for prostatic acid phosphatase |
| US4624916A (en) * | 1984-04-06 | 1986-11-25 | International Immunoassay Laboratories, Inc. | Process and composition for the rapid quantitation of small levels of creative kinase-MB isoenzyme |
| US4560504A (en) * | 1984-12-06 | 1985-12-24 | Uop Inc. | Carboxyl anchored immobilized antibodies |
| IE59210B1 (en) * | 1985-11-14 | 1994-01-26 | Univ Washington | Creatine kinase mb determination method |
| US4912033A (en) * | 1985-11-14 | 1990-03-27 | Washington University | Creatine kinase MB determination method |
| US4810639A (en) * | 1985-12-20 | 1989-03-07 | E. I. Du Pont De Nemours And Company | Immunoassay for CK-MB using bound and soluble antibodies |
| US4897346A (en) * | 1986-07-15 | 1990-01-30 | Beckman Instruments, Inc. | Stabilized liquid enzyme composition for glucose determination |
| JPS63131065A (ja) * | 1986-11-20 | 1988-06-03 | Yatoron:Kk | æäœã®ç²Ÿè£œæ³ãšã¢ã€ãœã¶ã€ã ã®æž¬å®æ³åã³è©Šè¬ |
| US4900662A (en) * | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
| US4837163A (en) * | 1987-10-02 | 1989-06-06 | Tsuyoshi Ohnishi | Simple blood test for diagnosing malignant hyperthermia |
| GB8822180D0 (en) * | 1988-09-21 | 1988-10-26 | Glaverbel | Separation of product of biological process from fluid medium |
| US5369006A (en) * | 1991-08-20 | 1994-11-29 | E. I. Du Pont De Nemours And Company | Determination of CK isoenzymes and CK isoforms |
| KR20080114689A (ko) | 2006-02-09 | 2008-12-31 | ì ëë²ìí° ì€ëž ì¬ì°ì€ íë¡ëŠ¬ë€ | ìŠê°ë ïœïœïœ-2ì ìí ìì ë°ê²¬ |
| US9360398B2 (en) | 2007-09-11 | 2016-06-07 | University Of Florida Research Foundation, Inc. | Devices and methods for the collection and detection of substances |
| WO2009036168A2 (en) * | 2007-09-11 | 2009-03-19 | University Of Florida Research Foundation, Inc. | Devices and methods for the collection and detection of substances |
| US9207242B2 (en) | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
| NL154599B (nl) * | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| FR2192144A1 (en) * | 1972-07-10 | 1974-02-08 | Miles Lab | Specific isoenzyme antibodies polymn - for determination of isoenzyme in liq specimens |
| DE2258822A1 (de) * | 1972-12-01 | 1974-06-06 | Merck Patent Gmbh | Verfahren und mittel zur analyse von isoenzymmustern |
| US3994783A (en) * | 1975-09-26 | 1976-11-30 | Calbiochem | Differential assay of creatine phosphokinase isoenzymes |
| DE2548963C3 (de) * | 1975-11-03 | 1982-03-11 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren und Mittel zur Bestimmung der AktivitÀt von Creatinkinase-MB |
| US4049496A (en) | 1976-05-27 | 1977-09-20 | Henry Philip D | Rapid separation of plasma creatine kinase isoenzymes |
-
1979
- 1979-02-23 US US06/014,315 patent/US4260678A/en not_active Expired - Lifetime
-
1980
- 1980-02-04 JP JP1235680A patent/JPS55107958A/ja active Granted
- 1980-02-19 DE DE19803006118 patent/DE3006118A1/de active Granted
- 1980-02-19 AU AU55710/80A patent/AU529444B2/en not_active Ceased
- 1980-02-20 GB GB8005680A patent/GB2043894B/en not_active Expired
- 1980-02-21 FR FR8003812A patent/FR2449895A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2449895B1 (ja) | 1985-03-01 |
| GB2043894A (en) | 1980-10-08 |
| US4260678A (en) | 1981-04-07 |
| FR2449895A1 (fr) | 1980-09-19 |
| GB2043894B (en) | 1983-05-25 |
| AU529444B2 (en) | 1983-06-09 |
| JPS55107958A (en) | 1980-08-19 |
| DE3006118C2 (ja) | 1988-09-15 |
| AU5571080A (en) | 1980-08-28 |
| DE3006118A1 (de) | 1980-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6331741B2 (ja) | ||
| Chang et al. | Induction of DNA polymerase in mouse L cells | |
| EP0239318B1 (en) | Assay employing binding pair members on particles and on a filter or membrane | |
| JP3706890B2 (ja) | è©Šæäžã®çç©ãæ€åºããæ¹æ³ | |
| Shimizu et al. | Nucleotide specificity of the enzymatic and motile activities of dynein, kinesin, and heavy meromyosin. | |
| EP0310251B1 (en) | DNA detection system | |
| EP0937250B1 (en) | A solid phase cell-based assay | |
| Ossmer et al. | Immunocytochemical localization of component C of the methylreductase system in Methanococcus voltae and Methanobacterium thermoautotrophicum | |
| US4387160A (en) | Immunochemical assay for creatine kinase-MB isoenzyme | |
| Weibel et al. | Insolubilized coenzymes: the covalent coupling of enzymatically active NAD to glass surfaces | |
| FR2521303A1 (fr) | Procede de determination immunologique d'anticorps de type immunoglobuline de classe specifique | |
| Trotta et al. | A normal level of adenosine deaminase activity in the red cell lysates of carriers and patients with severe combined immunodeficiency disease. | |
| FI83669B (fi) | Foerfarande foer specifik bestaemning av pankreas -amylas. | |
| JP2002199875A (ja) | è±çªæ¹æ³ | |
| US4278761A (en) | Enzyme assay and kit therefor | |
| Schrier et al. | Characterization of erythrocyte membrane-associated enzymes (glyceraldehyde-3-phosphate dehydrogenase and phosphoglyceric kinase) | |
| GB2190194A (en) | Method for determination of antigen | |
| EP0914465A1 (en) | Materials and methods for detecting oxalate | |
| Pundir et al. | Immobilization of Arthrobacter sarcosine oxidase onto alkylamine and arylamine glass and its application in serum sarcosine determination | |
| JPS63501982A (ja) | ã¯ã¬ã¢ãã³ããâãŒïœïœå®éæ¹æ³ | |
| Landt et al. | Immunoaffinity purification of creatine kinase-MB from human, dog, and rabbit heart with use of a monoclonal antibody specific for CK-MB. | |
| JPH02245199A (ja) | ã¢ã€ãœã¶ã€ã æ··åç©ããïŒã€ã®é µçŽ ã枬å®ããæ¹æ³åã³ãã¹ãæ äœ | |
| EP0200539B1 (en) | Method of preparing coating compositions containing antisera and elements containing same | |
| US4254218A (en) | Detecting Neisseria via immobilized antibody-enzyme complex | |
| Horowitz et al. | Generalized affinity chromatography: enzyme-sulfonamide conjugates can be isolated by adsorption on immobilized carbonic anhydrase |